Treatment with the investigational therapy encaleret normalized calcium levels for most people with chronic hypoparathyroidism in a small proof-of-principle study. That’s according to data announced by Bridgebio Pharma, which is developing encaleret with its affiliate Calcilytix Therapeutics. The company said it hopes to launch a clinical trial…